Stemcell United Stock

Stemcell United Equity

The The Equity of Stemcell United (SCU.AX) as of Sep 8, 2026 is 3.04 M AUD. In the previous year, The Equity was 5.55 M AUD — a change of -45.11% (lower).

Equity

3.04 MAUD

YoY

-45.11%

Last updated:

In 2026, Stemcell United's equity was 3.04 M AUD, a -45.11% increase from the 5.55 M AUD equity in the previous year.

The Stemcell United Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
149,850.00 AUD
Jan 1, 2016
4.15 M AUD
Jan 1, 2017
2.12 M AUD
Jan 1, 2018
1.20 M AUD
Jan 1, 2019
1.69 M AUD
Jan 1, 2020
441,450.00 AUD
Jan 1, 2021
5.55 M AUD
Jan 1, 2022
3.04 M AUD
The Stemcell United Equity history
YEAREquityYoY
3.04 MAUD-45.11%
5.55 MAUD+1,156.23%
441,450.00AUD-73.86%
1.69 MAUD+40.65%
1.20 MAUD-43.48%
2.12 MAUD-48.87%
4.15 MAUD+2,672.48%
149,850.00AUD—
Access this data via the Eulerpool API
Get Free API Key

Stemcell United Stock analysis

What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Stemcell United's Equity

Stemcell United's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Stemcell United's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Stemcell United's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Stemcell United's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Stemcell United’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Stemcell United stock

The Equity of Stemcell United is 3.04 M AUD in 2026.

The Equity of Stemcell United changed from 5.55 M AUD to 3.04 M AUD, representing a -45.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Stemcell United since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Stemcell United historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Stemcell United

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Stemcell United